Equities
Health CarePharmaceuticals and Biotechnology
  • Price (CHF)39.76
  • Today's Change-0.86 / -2.12%
  • Shares traded632.20k
  • 1 Year change+62.42%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 16:39 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.

  • Revenue in CHF (TTM)--
  • Net income in CHF--
  • Incorporated2022
  • Employees23.85k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SDZ:SWX since
announced
Transaction
value
Coherus BioSciences Inc-CIMERLI BusinessDeal completed22 Jan 202422 Jan 2024Deal completed41.90%170.00m
Data delayed at least 15 minutes, as of Nov 12 2024 16:39 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cipla Ltd2.77bn466.93m13.08bn27.76k28.034.4222.704.7355.3955.39328.19351.200.8031.585.089,549,060.0013.5810.0916.4412.4067.0158.6316.9212.662.8269.410.01621.3913.289.5147.1021.9620.6834.08
Royalty Pharma plc2.00bn1.01bn13.68bn89.0010.312.2721.646.852.562.563.8011.630.1337--72.1525,460,710.0010.119.5713.3012.42----75.6467.80----0.425823.475.245.582,549.50-3.8050.99--
Viatris Inc13.25bn-777.92m13.76bn38.00k--0.78948.191.04-0.7389-0.738912.5416.580.32192.234.94396,013.20-1.890.0887-2.230.106142.4940.29-5.870.28910.96152.370.443560.11-5.146.17-97.37-30.53-16.88--
Incyte Corp3.59bn28.61m13.83bn2.52k582.574.96130.073.850.140.1418.7916.450.7154.235.761,614,842.000.56989.070.740411.0293.3794.970.796913.681.82--0.010.008.8714.4575.4240.41-15.06--
Divi's Laboratories Ltd898.79m191.57m16.34bn17.50k85.3311.4270.4918.1869.1469.14324.44516.710.57681.134.274,922,286.0012.2916.5513.3218.2259.9156.2421.3126.384.80--0.000634.320.99769.66-12.253.416.4713.40
Teva Pharmaceutical Industries Ltd14.76bn-873.64m17.37bn35.00k--3.26--1.18-3.27-3.2755.7420.050.40012.054.901,794,840.00-2.99-3.14-4.34-4.2951.0148.14-7.46-9.870.60564.720.7483--6.17-3.4277.15---4.17--
Astellas Pharma Inc10.15bn313.66m17.93bn14.75k56.862.0212.491.7730.4230.42986.34854.610.50601.363.39120,113,500.001.564.592.316.6181.7880.533.097.980.862315.320.377486.615.604.19-82.73-40.179.6213.00
Sandoz Group AG-100.00bn-100.00bn17.98bn23.85k--2.38----------17.14------------------------0.7401--0.3469--7.23---90.92------
Zhangzhou Pientzhng Phrmctcl Co Ltd1.33bn375.89m18.56bn2.79k49.3710.84--13.945.105.1018.0823.240.64011.6714.663,911,417.0018.2218.8222.5123.9143.9146.5528.4627.983.64--0.074736.4915.6916.1113.1519.6013.8331.06
Biogen Inc8.46bn1.42bn22.08bn7.57k15.541.5211.072.6111.0711.0765.83112.900.340.86044.581,269,155.005.7112.537.0114.8375.5983.0416.8026.930.80394.890.27780.00-3.32-6.07-61.89-23.58-18.87--
Bayer AG44.21bn-1.19bn22.51bn96.57k--0.67233.410.5092-1.29-1.2947.9636.330.39011.473.47472,438.70-1.04-1.79-1.42-2.3858.0759.02-2.67-4.800.85732.940.5651---6.115.33-170.87--1.19-47.66
Data as of Nov 12 2024. Currency figures normalised to Sandoz Group AG's reporting currency: Swiss Franc CHF

Institutional shareholders

18.76%Per cent of shares held by top holders
HolderShares% Held
UBS Asset Management Switzerland AGas of 30 Sep 202418.92m4.39%
The Vanguard Group, Inc.as of 02 Oct 202415.56m3.61%
Norges Bank Investment Managementas of 30 Jun 20249.86m2.29%
Z�rcher Kantonalbank (Investment Management)as of 30 Aug 20249.08m2.11%
BlackRock Fund Advisorsas of 03 Oct 20247.39m1.71%
Vontobel Asset Management AGas of 30 Sep 20244.89m1.14%
Geode Capital Management LLCas of 07 Nov 20243.99m0.93%
Boston Partners Global Investors, Inc.as of 03 Oct 20243.97m0.92%
Deka Investment GmbHas of 03 Oct 20243.82m0.89%
BlackRock Asset Management Schweiz AGas of 03 Oct 20243.40m0.79%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.